Using spatial multi-omics, researchers mapped changing macrophage populations across MASLD progression and identified markers that could support patient stratification in clinical trials. The study points toward more tissue-contextual immune profiling for metabolic dysfunction–associated steatotic liver disease, where trial design often struggles with heterogeneity.